Skip to content
lifestyle.tweeternet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 6, 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
May 28, 2026